```json
{
"content": [
{
"type": "paragraph",
"content": "Chlorhexidine gluconate (CHG) disposable wipes are single-use, non-woven pads impregnated with 2% w/v CHG solution—an essential infection-prevention tool in pre-operative and high-risk hospital zones."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Surgical Prep", "ICU Line Care",", "Outpatient Kits", "Emergency Kits"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[42, 48, 55, 62, 68, 73, 78, 83, 88, 92, 96, 100, 104, 108],
[28, 33, 38, 43, 48, 52, 56, 60, 64, 68, 71, 74, 77, 80],
[18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57],
[12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38]
]
}
},
{
"type": "paragraph",
"content": "Global market size is estimated at USD 1.2 billion in 2025 and forecast to reach USD 2.1 billion by 2033, translating to a 6.8% CAGR (2026-2033). Key growth engines are rising nosocomial infection rates, mandatory pre-op wipe protocols, and shift to single-use antiseptic formats post-COVID. North America commands the largest share (38%) thanks to bundled reimbursement in U.S. hospitals, while APAC (9% CAGR) is the fastest-expanding region due to diabetes-driven surgical volume and expanding private hospital networks. Competitive intensity is intensifying as suppliers move to chlorhexidine-alcohol combos, biodegradable substrates, and custom kit customization to defend differentiation amid raw-material supply tightness (polypropylene non-woven costs +12% YoY) and tightening EU MDR compliance. Overall growth outlook remains bullish as hospital tenders increasingly specify 2% CHG** wipes over iodine-based lines."
}
]
}
```
